English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 31 October 2014, 10:00 HKT/SGT

Source: Lubrizol
Lubrizol Forms Alliance with Particle Sciences after Vesta Acquisition
Alliance of World-Class CMO with leading drug product formulator creates fully integrated CDMO focusing on advanced drug delivery and combination products

CLEVELAND, Ohio, Oct 31, 2014 - (ACN Newswire) - The Lubrizol Corporation announces an alliance between Lubrizol LifeSciences, a leading supplier of advanced materials for the healthcare industry, and Particle Sciences, an integrated provider of drug development services. This alliance offers customers a comprehensive solution providing a range of materials, drug development and commercial manufacturing services that is one of the most comprehensive in the pharmaceutical industry.

Lubrizol's recent acquisition of contract manufacturer Vesta, in combination with Lubrizol's alliance with Particle Sciences, means that the LifeSciences business now offers complete solutions for sustained, controlled release and combination products from polymer supply and drug product development through quality manufacturing services. Lubrizol LifeSciences (booth 1817) will officially launch its alliance with Particle Sciences (booth 2911) at the American Association of Pharmaceutical Scientists (AAPS) conference Nov. 2-6 at the San Diego Convention Center.

"We've broadened our offering and further reinforced our commitment to the pharmaceutical market," says Jean Claude Deneuville, Lubrizol LifeSciences director of the Pharma Solutions business. "By joining forces with Vesta and working with Particle Sciences, we have further expanded our set of skills and brought full-service solutions to the market." Lubrizol LifeSciences now offers a combination of world class polymer technology, drug product development services, clinical supply, applications know-how and commercial manufacturing.

"Teaming up with both Vesta and Particle Sciences enables Lubrizol to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems and combination products to deliver improved patient outcomes," says Joey Glassco, global market manager for Lubrizol LifeSciences.

Particle Sciences, based in Bethlehem, PA., is one of the world's leading contract drug development and manufacturing organizations (CDMO) with a comprehensive suite of services including analytic, bio-analytic, physical characterization and manufacturing, all focused on the formulation and support of advanced drug delivery solutions. Its leadership in drug eluting product development and breadth of development technologies has earned it business with life sciences companies ranging from start-ups to more than half of the top 10 pharmaceutical and biotech leaders.

The recent acquisition of Vesta, a leading contract manufacturer to the medical device industry, broadens Lubrizol's life science manufacturing capabilities, applications and material portfolio with access to silicone polymers and a variety of thermoplastics utilized in medical devices, advanced wound care and drug eluting products such as subcutaneous implants and intravaginal rings. Headquartered in Franklin, WI, Vesta leverages over four decades of engineering expertise and manufacturing experience to service clinical device applications with the quality that customers trust.

For more information, contact Lubrizol LifeSciences at +1-888-234-2436 or visit www.lubrizol.com/lifesciences.

The Lubrizol Corporation

The Lubrizol Corporation, a Berkshire Hathaway company, is a technology-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It produces and supplies technologies to customers in the global transportation, industrial and consumer markets. These technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care and personal care products and pharmaceuticals, and specialty materials, including plastics technology and performance coatings in the form of specialty resins and additives.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 7,500 employees worldwide. Revenues for 2013 were $6.4 billion. For more information, visit www.Lubrizol.com.

Media Contact
Ben Patti


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Lubrizol via Globenewswire

Topic: Press release summary
Source: Lubrizol

From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Lubrizol Releated News
June 18, 2019 16:30 HKT/SGT
Lubrizol Announces Global Collaboration with Corbion
May 29, 2019 10:00 HKT/SGT
Particle Sciences Expands Controlled Substance Capabilities with Approval of DEA Schedule I Registration
May 29, 2019 10:00 HKT/SGT
Lubrizol to Present at the 29th CIMAC World Congress 2019
May 17, 2019 08:00 HKT/SGT
Lubrizol Aims at Circular Economy with TPU Solutions for Footwear
May 15, 2019 09:00 HKT/SGT
Lubrizol Announces Collaboration with Ultimaker's Material Alliance Program
More news >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575